文献速递胃肠动力与功能性疾病

丁螺环酮治疗早饱与胃轻瘫症状:多中心、随机、安慰剂对照、双盲试验(BESST)

Buspirone for early satiety and symptoms of gastroparesis: A multi-centre, randomised, placebo-controlled, double-masked trial (BESST).
PubMed 文献 · Aliment Pharmacol Ther · 2023-04-13

这项为期4周的多中心随机双盲安慰剂对照试验纳入96例有胃轻瘫症状且早饱/餐后饱胀为中重度的患者,比较丁螺环酮10 mg每日三次与安慰剂的疗效。主要终点早饱/餐后饱胀评分变化两组无显著差异,但在基线腹胀较重的患者中丁螺环酮似有获益。

要点

  • 丁螺环酮10 mg每日三次治疗4周,早饱/餐后饱胀评分改善与安慰剂无显著差异。
  • 基线腹胀严重至非常严重的患者中,丁螺环酮似有获益,交互作用p=0.003(Bonferroni校正后p=0.07)。
  • 单个胃轻瘫 cardinal 症状中仅腹胀似有改善。

核心结论

  • 有中重度早饱/餐后饱胀及其他胃轻瘫症状的患者,丁螺环酮治疗未较安慰剂改善早饱/餐后饱胀主要终点。
  • 基线腹胀更严重的患者中丁螺环酮似有获益。

研究设计与样本

  • 4周多中心随机、安慰剂对照、双盲试验,纳入有胃轻瘫症状且早饱/餐后饱胀为中重度的患者。
  • 96例患者随机接受丁螺环酮10 mg口服每日三次(47例)或安慰剂(49例);92%女性,50%胃排空延迟,39%糖尿病。
  • 主要分析为符合方案意向性分析(ANCOVA),比较两组基线至4周早饱/餐后饱胀评分差值,校正基线评分。

主要发现

  • 4周早饱/餐后饱胀主要终点两组无差异:丁螺环酮组-1.16±1.25(SD) vs 安慰剂组-1.03±1.29(SD),均值差-0.11(95%CI:-0.68,0.45),p=0.69。
  • 基线腹胀严重至非常严重者与无至中度者相比,丁螺环酮早饱/餐后饱胀差值-0.65 vs 1.58,交互作用p=0.003,Bonferroni校正p=0.07。
  • 单个胃轻瘫 cardinal 症状中仅腹胀似有改善。

关键数值与推荐

  • 主要终点早饱/餐后饱胀评分变化两组无显著差异,均值差-0.11(95%CI:-0.68,0.45),p=0.69。
  • 基线腹胀严重至非常严重亚组交互作用p=0.003,Bonferroni校正p=0.07。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. Buspirone, a 5-HT1 receptor agonist, may improve fundic accommodation. AIM: To determine if buspirone treatment improves early satiety and postprandial fullness in patients with symptoms of gastroparesis. METHODS: This 4-week multi-centre clinical trial randomised patients with symptoms of gastroparesis and moderate-to-severe symptoms of fullness (Gastroparesis Cardinal Symptom Index [GCSI] early satiety/postprandial fullness subscore [ES/PPF]) to buspirone (10 mg orally) or placebo three times per day. The primary outcome was a change in the ES/PPF from baseline to 4 weeks. The primary analysis was per protocol intention-to-treat ANCOVA of between-group baseline vs. 4-week differences (DoD) in ES/PPF adjusted for baseline ES/PPF. Results are reported using both nominal and Bonferroni (BF) p values. RESULTS AND CONCLUSIONS: Ninety-six patients (47 buspirone, 49 placeboes; 92% female, 50% delayed gastric emptying, 39% diabetic) were enrolled. There was no between-groups difference in the 4-week ES/PPF primary outcome: -1.16 ± 1.25 (SD) on buspirone vs -1.03 ± 1.29 (SD) on placebo (mean DoD: -0.11 [95% CI: -0.68, 0.45]; p = 0.69). Buspirone performed better than placebo in patients with severe-to-very severe bloating at baseline compared to patients with none to moderate: (ES/PPF DoD = -0.65 vs. 1.58, pTX*GROUP = 0.003; pBF = 0.07). Among individual GCSI symptoms, only bloating appeared to improve with buspirone vs. placebo. CONCLUSIONS: Patients with moderate-to-severe early satiety/postprandial fullness and other symptoms of gastroparesis did not benefit from buspirone treatment to improve the ES/PPF primary outcome compared with placebo. There was a suggestion of the benefit of buspirone in patients with more severe bloating. TRIAL REGISTRATION: ClinicalTrials.gov NCT0358714285.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Parkman HP, Yates KP, Sarosiek I, et al. Buspirone for early satiety and symptoms of gastroparesis: A multi-centre, randomised, placebo-controlled, double-masked trial (BESST). Aliment Pharmacol Ther. 2023. PMID: 37052334. doi:10.1111/apt.17479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。